Risk factors for drug-related cachexia: an analysis based on the FDA adverse event reporting system (FAERS) from 2004 to 2025. (PubMed, Front Pharmacol) - Sep 24, 2026 - "The drugs with stronger signals were low calcium peritoneal dialysis solution lactate G15 (ROR 495.67, 95% CI 336.94-729.18), Kaletra (ROR 10.44, 95% CI 7.98-13.65), and nivolumab (ROR 15.29, 95% CI 13.65-17.13). The drugs with a higher number of reported cases were nivolumab (319 cases), paclitaxel (160 cases), and Zometa (131 cases)...Cachexia is more likely to occur in the initial stage of drug treatment and has a high mortality rate. Continuous regulatory review and label updates of the safety information of relevant medications should be promoted."
Adverse events • Journal • Cachexia • Metabolic Disorders • Oncology
|
|
Jie Ni; Lingli Huang; Quanli Zhang; Shuchen Dong
|